Background: IgD is an enigmatic antibody isotype best known when coexpressed with IgM on naive B cells. However, increased soluble IgD (sIgD) levels and increased IgD 1 IgM 2 B-cell populations have been described in the human upper respiratory mucosa. Objective: We assessed whether levels of sIgD and IgD 1 B cell counts are altered in nasal tissue from patients with chronic rhinosinusitis (CRS). We further characterized IgD 1 B-cell populations and explored clinical and local inflammatory factors associated with tissue sIgD levels. Methods: sIgD levels were measured by means of ELISA in nasal tissues, nasal lavage fluid, sera, and supernatants of dissociated nasal tissues. IgD 1 cells were identified by using immunofluorescence and flow cytometry. Inflammatory mediator levels in tissues were assessed by using real-time PCR and multiplex immunoassays. Bacterial cultures from the middle meatus were performed. Underlying medical history and medicine use were obtained from medical records. Results: sIgD levels and numbers of IgD 1 cells were significantly increased in uncinate tissue (UT) of patients with chronic rhinosinusitis without nasal polyps (CRSsNP) compared with that of control subjects (4-fold, P < .05). IgD 1 cells were densely scattered in the periglandular regions of UT from patients with CRSsNP. We also found that IgD 1 CD19 1 CD38 bright plasmablast numbers were significantly increased in tissues from patients with CRSsNP compared with control tissues (P < .05). Among numerous factors tested, IL-2 levels were increased in UT from patients with CRSsNP and were positively correlated with tissue IgD levels. Additionally, supernatants of IL-2-stimulated dissociated tissue from patients with CRSsNP had significantly increased sIgD levels compared with those in IL-2-stimulated dissociated control tissue ex vivo (P < .05). Tissue from patients with CRS with preoperative antibiotic use or those with pathogenic bacteria showed higher IgD levels compared with tissue from patients without these variables (P < .05). Conclusion: sIgD levels and IgD 1 CD19 1 CD38 bright plasmablast counts were increased in nasal tissue of patients with CRSsNP. IgD levels were associated with increased IL-2 levels and the presence of pathogenic bacteria. These findings suggest that IgD might contribute to enhancement mucosal immunity or inflammation or respond to bacterial infections in patients with CRS, especially CRSsNP. (J Allergy Clin Immunol 2017;140:1562-71.)
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Chronic rhinosinusitis (CRS) is a heterogeneous clinical condition associated with significant quality-of-life impairment and persistent local inflammation of the sinonasal mucosa. [1] [2] [3] [4] CRS is usually subdivided into 2 clinical subgroups: chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). [5] [6] [7] Although CRSsNP is 5-to 10-fold more prevalent, it remains poorly characterized compared with CRSwNP. One potential reason is that CRSsNP encompasses a wider variety of CRS subtypes/endotypes with more heterogeneous inflammatory patterns in US-based studies, whereas CRSwNP is more homogeneously characterized by type 2 inflammation in Western populations. [8] [9] [10] [11] [12] Regardless of subgroup, it is likely that the host immune system plays a prominent role in CRS pathogenesis. 1, 13 B cells represent a major component of adaptive immune responses, which participate in both immunity and inflammation through their production of antibodies.
14 Five isotypes of antibodies, including IgM, IgD, IgG, IgA, and IgE, are encoded in human subjects and rodents. 15 Of these, IgM, IgG, IgA, and IgE have been described at increased levels in nasal polyps (NPs) from patients with CRSwNP compared with tissue from control subjects. 16, 17 Despite its discovery more than 40 years ago, IgD has remained largely underexplored in patients with inflammatory diseases, including CRS. 18 IgD is best characterized in transitional and mature naive B cells in which membrane IgD (mIgD) is coexpressed with membrane IgM, bearing the same variable region and antibody specificity. 19, 20 Translation of mIgD occurs through alternative splicing of a premRNA composed of V(D)J and both heavy-chain Cm and Cd exons. After antigenic stimulation, follicular B cells will transcriptionally downregulate mIgD in a germinal center reaction and undergo somatic hypermutation and class-switch recombination of DNA to express IgM, IgG, IgA, and IgE. 20, 21 In contrast to mice, in which mIgD expression is restricted to transitional and naive B cells, human B cells can additionally express mIgD on a unique set of circulating IgM 26, 27 Together, these data suggest that IgD-secreting B cells are activated in the human upper airway, but whether they are associated with specific inflammatory conditions, such as CRS, and their precise role in mucosal immunity remain unclear.
In this study we sought to investigate whether levels of sIgD and IgD 1 B cells are aberrant in nasal tissue from patients with CRS. We further characterized the phenotype of IgD 1 B-cell populations within nasal tissue and explored which local factors could affect IgD production in vivo and in vitro. Finally, we assessed clinical parameters associated with IgD in nasal tissue.
METHODS

Subjects and sample collection
Control subjects and patients with CRS were recruited from the Otolaryngology and Allergy-Immunology Clinics at Northwestern Medicine or the Department of Otolaryngology at Stanford University. Demographic and underlying medical history and history of antibiotic and corticosteroid use within 4 weeks of sinus surgery were obtained from electronic medical records. Preoperative computed tomographic scans were graded according to methods defined by Lund and Mackay. 28 Subjects' characteristics are included in Table E1 in this article's Online Repository at www.jacionline.org. All subjects provided informed consent. The Institutional Review Boards of Northwestern University Feinberg School of Medicine and Stanford University School of Medicine approved this study.
Tissue specimens, including uncinate tissue (UT), ethmoid sinus tissue (ET), and NPs; nasal lavage fluid; and sera were obtained from subjects and prepared as previously described. 12, 29 Further details are provided in the Methods section in this article's Online Repository at www.jacionline.org.
ELISA
We measured IgD protein concentrations using the Human IgD ELISA Quantitation set (Bethyl Laboratories, Montgomery, Tex). Additionally, we measured eosinophil cationic protein (ECP) levels using the Mesacup ECP Test (MBL International, Woburn, Mass). Tissue concentrations of IgD and ECP were normalized to the total protein concentration measured by using the BCA Protein Assay (Thermo Fisher Scientific, Waltham, Mass).
Immunofluorescence
Immunofluorescence was performed, as described previously. 17 Briefly, blocked sections were stained with phycoerythrin-conjugated goat anti-human IgD antibody (SouthernBiotech, Birmingham, Ala). Further detailed methods are provided in the Methods section in this article's Online Repository. 
Abbreviations used
Cell isolation and flow cytometry
Cells were isolated from ET and whole blood samples from the same subjects. Isolated cells were stained for flow cytometric analysis with various B-cell surface markers, including CD19, CD20, CD27, CD38, CD138, IgM, and IgD. A cocktail of antibodies to CD45, CD3, CD14, CD16, and CD56 was used in a dump channel to exclude non-B-cell immunocytes. Furthermore, intracellular IgD and BLIMP-1 staining was performed by using the Cytofix/ Cytoperm Kit (BD Biosciences, Franklin Lakes, NJ). All conjugated antibodies were individually titrated to maximize specificity while accurately compensating for 12-color, 20-parameter, high-dimensional fluorescenceactivated cell sorting (FACS). The reagent targeting intracellular IgD was conjugated to a fluorophore the emission of which is distinct from that of mIgD. For flow cytometric analysis, 1 3 10 6 events (minimum) were collected for each sample at the Stanford Shared FACS Facility on a FACS-LSRII.2 (BD Biosciences, San Jose, Calif). Data were analyzed with FlowJo software (FlowJo, Ashland, Ore). Further detailed methods and gating strategies are provided in Fig E1 and the Methods section in this article's Online Repository at www.jacionline.org.
Ex vivo tissue explant culture
Cells were isolated from nasal tissue by using a modified method designed for cutaneous tissue, as previously described. 17, 30 Briefly, tissue samples obtained from sinus surgery were placed in 5 mL of RPMI 1640 medium (Life Technologies, Grand Island, NY) supplemented with 5% fetal calf serum (FCS; Atlanta Biologicals, Lawrenceville, Ga), 1 mmol/L sodium pyruvate (Life Technologies), 1% penicillin/streptomycin, and 60 U/mL IL-2 (Conditioned-RPMI [C-RPMI]; Life Technologies). Tissue was incubated in C-RPMI for 4 days at 378C in a 5% CO 2 atmosphere. Remaining tissue fragments were removed through a 70-mm Falcon cell strainer (Thermo Fisher Scientific), and supernatant was stored at 2208C until use. 
Luminex assay
Real-time PCR
mRNA levels of IL-2, IL-21, IL-15, CD40 ligand (CD40L), and B cell-activating factor (BAFF) in total RNA isolated from whole nasal tissues were measured by using quantitative real-time PCR, as detailed in the Methods section in this article's Online Repository.
Nasal swab culture
A nasal swab of the middle meatus for bacterial culture was obtained before initiating surgery from control subjects and patients with CRS. The middle meatus is an anatomic drainage space within the ethmoid sinuses from which tissue samples were also harvested. Cultures obtained from this location reliably reflect the microbiology of the sinus cavities. 31 All specimens were obtained with a sterile swab (BBL CultureSwab; Becton Dickinson) and sent immediately to the laboratory of the Department of Microbiology at Northwestern Medicine for routine aerobic microbiological cultures. Further details are described in the Methods section in this article's Online Repository.
Statistical analyses
All data are reported as means 6 SEMs, unless otherwise noted. Differences between groups were analyzed by using the Mann-Whitney U test or Kruskal-Wallis test with the Dunn correction for multiple comparisons. Correlations were assessed by using Spearman rank correlation. All statistical analysis was performed with GraphPad Prism 6 software (GraphPad Software, San Diego, Calif), and a P value of less than .05 was considered statistically significant.
RESULTS sIgD levels were increased in nasal airway mucosa from patients with CRSsNP
We first assessed protein levels of sIgD in nasal tissues, nasal lavage fluid, and sera. sIgD levels were significantly increased in UT from patients with CRSsNP (mean, 532.3 ng/mg total protein) compared with those in control UT (mean, 125.8 ng/mg total protein; P < .05; Fig 1, A) , demonstrating a bimodal separation into patients with high IgD levels and those with low IgD levels. Although sIgD levels were not significantly increased in the nasal lavage fluid of patients with CRSsNP, we found a subpopulation with high IgD levels in both the CRSsNP and CRSwNP patient groups (Fig 1, B) . Furthermore, there was a significant positive correlation between sIgD levels in patients for whom we had both tissue and nasal lavage measurement (r 5 0.30, P 5 .02, n 5 55; data not shown). Additionally, there were no significant differences in sIgD levels in serum of patients with CRSsNP compared with that of control subjects (Fig 1, C) .
IgD
1 B-cell counts were increased in nasal airway mucosa of patients with CRS
We next sought to determine whether IgD 1 B cells were present in nasal tissue by performing immunofluorescence. Within each disease group, 15 surgical samples from the same patients whose tissue homogenates were used for IgD protein analysis were used for immunofluorescence. Although rare IgD 1 cells were detected in UT from control subjects (Fig 2,  A) , there were samples with abundant IgD 1 cells, especially in UT from patients with CRSsNP (Fig 2, B) . IgD 1 cells were also observed in UT and NPs of patients with CRSwNP, although to a lesser extent (Figs 2, C and D, respectively). Interestingly, IgD 1 cells were predominantly located in periglandular areas in UT from patients with CRSsNP ( Fig 2, E) ; only 13.3% (n 5 2) of patients with CRSsNP demonstrated the presence of subepithelial IgD 1 cells (Fig 2, F) . In contrast, IgD 1 cells in NP tissues were enriched in the subepithelial region (73.3% of tested patients with CRSwNP; Fig 2, G and H). When observed, the IgD 1 cells had small nuclei with intense and uniformly stained cytoplasm consistent with plasma cells or plasmablasts. A semiquantitative analysis of immunofluorescence staining showed that the number of IgD 1 cells was increased in nasal tissues from patients with CRS, but a statistically significant increase was only observed when UT from patients with CRSsNP was compared with UT from control subjects (P < .05; Fig 2, I) , although even among patients with CRSsNP, a bimodal distribution concordant with our ELISA results was observed. Furthermore, we found that the number of IgD 1 cells in the immunofluorescence study was positively correlated with sIgD tissue levels measured by using ELISA (r 5 0.30, P 5 .02, n 5 60; Fig 2, J) .
1 plasmablast populations were exclusively found in nasal airway mucosa from patients with CRS Given that local mucosal, but not systemic, sIgD levels were increased and accumulated IgD 1 cells were also found in nasal tissue of patients with CRSsNP, we next sought to characterize the phenotype of these IgD 1 B cells using FACS. After performing a sequential FACS gating strategy (see Fig E1) , CD19 1 CD20 2 B cells were segregated into the IgD 1 plasmablast population by using IgD 1 and CD38 bright cells (Fig 3) . Although CD19 1 CD20 1 B cells in both peripheral blood and nasal tissues strongly expressed IgM, we found that both CD20 and IgM were absent in IgD 1 plasmablasts. As expected for this subpopulation, 21, 24 IgD 1 CD38 bright plasmablasts had dim expression of CD27 and low/negative surface IgM and did not express CD138 (Fig 3, A-C) . Furthermore, we found that only the IgD
1
CD38
bright cell population expressed both intracellular IgD and intracellular BLIMP-1 (Fig 3, D 
2 cells in the same plot, IgD 1 CD38 bright plasmablast populations had increased forward scatter (FSC) and side scatter (SSC) profiles, indicating larger cell size and increased granularity (Fig 3, F vs L 
CD19
1 CD20 2 CD38 bright ) was consistently detected in nasal tissues of patients with both types of CRS but not control subjects. Consistent with our ELISA and immunofluorescence results, numbers of these cells were significantly increased in patients with CRSsNP tissues compared with control subjects (0.02% and 0.00% of total cells, respectively; P < .01; Fig 4, A) . No IgD 1 plasmablasts were detected in the blood of either patients with CRS or control subjects from whom nasal tissue was obtained (Fig 4, B) .
IL-2 expression correlated with sIgD levels in nasal airway mucosa in vivo
Previous in vitro studies of B cells within tonsillar tissues determined that differentiation into IgD-producing B cells could be affected by CD40L, BAFF, or a proliferation-inducing ligand and various combinations of cytokines, including IL-2, IL-4, IL-10, IL-15, IL-21, and IFN-g. 21 ,32 Therefore we next sought to evaluate whether local levels of these mediators were increased in patients with CRSsNP and correlated with sIgD levels in nasal tissue. Of the aforementioned molecules, only gene expression levels of IL-2 (see Fig E2, A, in this article's Online Repository at www.jacionline.org) and IL-21 (data not shown) were significantly increased in both UT from patients with CRSsNP and NPs from patients with CRSwNP compared with UT from control subjects. There was a similar trend in IL-2 protein levels, although this did not reach statistical significance (see Fig E2, B) . Interestingly, we found a significant positive correlation between levels of sIgD and IL-2 proteins in nasal tissues among all patients (r 5 0.41, P 5.01; Fig 5) , with similar significant correlations for IL-2 mRNA expression (data not shown). Compared with control subjects, we could not find significant differences in protein levels of IL-4, IL-21, or IFN-g or gene expression of IL-15, CD40L, or BAFF in UT from patients with CRS. Protein levels of IL-10 and gene expression levels of BAFF were significantly different between NPs from patients with CRSwNP and UT from control subjects (see Fig E2, C and D) . With the exception of IL-2, protein or gene expression levels of the tested mediators did not correlate with measured IgD protein levels (data not shown).
IL-2 enhanced IgD production by CRSsNP nasal airway mucosa
Given that local IL-2 protein levels were associated with IgD levels in vivo, we performed ex vivo analysis to evaluate whether IgD production by nasal tissue after IL-2 stimulation differed among CRS subtypes. To do this, we cultured intact nasal tissue explants from control subjects, patients with CRSsNP, and patients with CRSwNP in the presence of IL-2 for 4 days and assessed the protein levels of sIgD in supernatants. sIgD levels released into supernatants of explants from patients with CRSsNP were significantly higher compared with those of control subjects (4-fold, P < .05; Fig 6) . Taken together, these data suggest that IL-2 levels that were significantly increased in patients with CRSsNP might prime IgD production.
Comparison of clinical characteristics of high-IgD versus low-IgD groups
Because sIgD levels and IgD 1 cells in nasal tissues appeared bimodally distributed with high and low IgD expression (Fig 1,  A) , we established thresholds for defining groups with high or low IgD levels using the 95th percentile of expression of control UT, as used in prior studies. 9, 33 On electronic medical records review, clinical features, including medication prescriptions, were extracted. As shown in Table I , patients in the group with a high IgD level more frequently had CRSsNP compared with the cohort with low IgD levels (75.0% vs 43.7%, respectively; P 5 .05). Interestingly, patients in the group with high IgD levels were more likely to have been prescribed an antibiotic within the 4 weeks before sinus surgery than those in the group with low IgD levels (33.3% vs 6.3%, respectively; P 5 .01). The mean tissue IgD level of patients with preoperative antibiotic use was 1156 ng/mg total protein, whereas that of patients without preoperative antibiotic use was 264.5 ng/mg total protein (P 5 .04; Fig 7, A) . No other clinical parameters were significantly divergent between these 2 groups.
Increased IgD levels correlated with pathogenic bacterial infection
Recent research suggests that IgD has the potential to enhance immune surveillance by activating antimicrobial programs. 24 However, the contributions of increased local IgD levels in patients with specific infectious conditions is unknown, although selected studies described an association between chronic infections and increased systemic IgD levels. 26, 27, 34 Informed by our findings above that high IgD tissue levels can be linked to recent antibiotic use in patients with CRS, we initiated a prospective study to evaluate the association between sinus bacterial infection and tissue IgD levels. Middle meatal swab 
CD38
bright cells in nasal tissue from control subjects, patients with CRSsNP, and those with CRSwNP (A) and in peripheral blood from the same patients (B). **P < .01, Kruskal-Wallis test. Numbers in flow cytometric plots indicate relative percentages.
FIG 5. Correlation between levels of IgD and IL-2 in nasal tissue in vivo.
Protein levels of IL-2 in tissue were measured by using multiplex immunoassay, and IgD levels were measured by using ELISA. Correlation was assessed by using the Spearman rank test.
FIG 6. sIgD levels in ex vivo tissue explant culture. Whole tissue explants were cultured with IL-2 (60 U/mL) for 4 days, and sIgD levels in supernatants were measured by using ELISA. *P < .05, Kruskal-Wallis test.
aerobic cultures in an additional group of 4 control subjects and 47 patients with CRS were collected along with UT samples. Speciated pathogenic bacterial growth was found in 31.4% (n 5 16 including 1 control subject, 8 patients with CRSsNP, and 7 patients with CRSwNP) of the enrolled patients (n 5 51). Gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, and H influenzae, were detected in 3 patients, whereas gram-positive bacteria, including Staphylococcus aureus and Streptococcus pneumoniae, were detected in the remaining patients (n 5 13). IgD levels in UT were significantly higher in patients with pathogenic bacterial growth compared with those without bacterial growth (P < .05; Fig 7, B) . No significant differences were detected in IgD levels between patients with gram-positive versus gram-negative bacterial growth (data not shown).
DISCUSSION
In this study we presented novel evidence that sIgD levels (Fig 1) and numbers of IgD 1 cells (Fig 2) are significantly increased in nasal tissue of patients with CRSsNP compared with control subjects. Although patients with CRSwNP did not have significantly increased levels of IgD in nasal tissue, there were some patients who also had high levels of sIgD and IgD 1 cells. Overall, sIgD levels in tissue from patients with CRS appeared to have a bimodal distribution, with patients with CRSsNP more frequently having high sIgD levels than those with CRSwNP. Unlike prior descriptions that IgD 1 plasmablasts exist universally in nasal mucosa, 24 they were only increased in nasal mucosa of patients with CRS, particularly those with CRSsNP, but not in control nasal mucosa or in the blood of either patients with CRS or control subjects in this study. Interestingly, IgD 1 cells were concentrated in the periglandular submucosa in patients with CRSsNP and in the subepithelial area in patients with CRSwNP (Fig 2) . The IgD 1 cells had a plasma cell-like morphology on immunofluorescence, but detailed flow cytometric phenotyping found that most IgD 1
CD19
1 CD38 bright B cells also expressed intracellular IgD 1 and BLIMP-1 1 without CD138, thus harboring features of plasmablasts (Fig 3) .
We next identified the local factors that associated with increased IgD levels and found that IL-2 levels correlated with IgD secretion in vivo (Fig 5) with supporting ex vivo results (Fig 6) . Furthermore, we showed compelling evidence that preoperative antibiotic use (Table I and Fig 7, A) and the presence of pathogenic bacterial infection (Fig 7, B) were associated with higher IgD levels in nasal tissues from patients with CRS. Together, these findings suggest that bacterial Text in boldface indicates statistically significant differences for that variable between patients with CRS with high IgD levels and those with CRS with low IgD levels (P < .05).
FIG 7.
Preoperative antibiotic use and presence of pathogenic bacterial infection can influence IgD levels in nasal tissue. A, History of preoperative antibiotic use was obtained from electronic medical records. B, Nasal swab cultures were performed before sinus surgery. IgD levels in UT were measured by using ELISA. Dot plots illustrate individual data points, and solid lines represent means 6 SEMs. *P < .05.
infection and/or the induced inflammatory response can influence local IgD production in the setting of CRS. To our knowledge, this is the first in-depth study to identify that local increase of sIgD and IgD 1 plasmablast counts is associated with CRS.
In human subjects serum IgD is found at relatively lower concentrations than levels of IgG (approximately 100-fold higher), IgA, and IgM, but IgD is present at much higher levels than serum IgE. 34 sIgD is also present in various bodily fluids, including nasal, lacrimal, salivary, mammary, bronchial, and cerebrospinal fluids. 15, 21, 35 Notably, it has been shown that greater amounts of sIgD are present in nasal secretions compared with saliva 36 or intestinal mucosal fluid, suggesting that IgD can have a unique functional role in upper respiratory mucosal immunity. 37 The source of sIgD in the upper airway presumably derives from IgD 1
CD38
bright plasmablasts, which are usually found in secondary lymphoid organs, such as tonsils and adenoids. 23 Our study demonstrated that IgD secretion can also occur directly within inflamed nasal mucosa adjacent to surface epithelium and deeper secretory glands. Consistent with our flow cytometric results, previous studies have described surface markers for these cells to be IgM 2 IgD 1 CD38
1
, although expression of mature B-cell markers, such as CD20; memory B-cell markers, such as CD27; and mature plasma cell markers, such as CD138 and BLIMP-1, have been described more variably. 23, 24 In analysis of IgD 1 plasmablasts from nasal tissue, we consistently found increased intracellular IgD and BLIMP-1 but not CD138 expression. Additionally, immunofluorescence and flow cytometric results overlap and indicate that IgD plasmablasts are exclusively found in patients with CRS and are essentially undetectable in control nasal tissues. In patients with CRS, they are present in limited density but most frequently in those with CRSsNP. This signifies that immunoregulation of IgD and its corresponding B-cell precursors are uniquely tailored for the nasal tissue microenvironment in the setting of inflammatory responses found in patients with CRS. The factors that govern this specificity remain unclear at this point.
A significant challenge in dissecting the enigmatic role of IgD in immune physiology has been its inability to activate complement and undescribed Fc receptors on effector cells. Despite its unknown immunomodulatory function, high serum IgD levels are reported in patients with various diseases, including immunodeficiencies, autoimmune diseases, and allergic and infectious diseases. [38] [39] [40] Systemic IgD levels are also consistently higher in a group of hereditary periodic fever syndromes that have a number of upper airway manifestations. 21, 41 Despite increased tissue levels of sIgD, serum sIgD levels were not increased in patients with CRSsNP, indicating the restriction of IgD responses to upper airway sites. Given the periglandular localization of IgD 1 cells, we anticipated that IgD levels in nasal secretions would be correspondingly higher in patients with CRSsNP. However, we found that any differences were not statistically significant, despite the fact that IgD levels in nasal lavage fluid significantly correlated with tissue levels. It should be noted that the mechanism by which IgD crosses the airway epithelium remains unknown. Unlike IgM and IgA, transport of which across epithelium is actively regulated by the polymeric immunoglobulin receptor, an epithelial receptor for IgD has not been described. It is possible that IgD secretion can be induced only under specific conditions. In this study the specificity of the sIgD antibodies found in patients with CRSsNP was not assessed. However, other reports have demonstrated that mIgD interacts directly with 2 pathogens, M catarrhalis and H influenzae, commonly associated with acute rhinosinusitis. 26, 42 The effect of M catarrhalis on B cells is better documented and occurs through a nonimmune binding of the bacterial Moraxella species IgD-binding protein (MID) located within the mIgD constant region. MID binding to IgD triggers potent mitogenic responses in B cells akin to B-cell superantigens, such as Staphylococcus protein A (SpA). 42 Unlike SpA, which only binds to immunoglobulin variable chains expressed on a subset of B cells, IgD is universally expressed by all naive B cells, and it is not surprising that in vitro studies demonstrate that MID has stronger superantigenic effects than SpA. 42 Indeed, we find that increased IgD levels are associated with bacterial cultures with known superantigenic effects and active sinus infections being treated with antibiotics. Other groups reported that more than 90% of tonsil-derived IgD plasma cells use Igl, and there was unusually high use of specific V H segments reminiscent of a superantigen-driven response. 25 Because acute rhinosinusitis and CRS are distinguished only by duration of symptoms (<4 weeks vs >12 weeks of symptoms in patients with CRS 1 ), one can speculate that the superantigen effects of the acute sinusitis pathogens M catarrhalis, H influenzae, and S aureus might be of pathogenic relevance to CRS.
Our findings that sIgD and IgD plasmablast counts were most increased in tissue from patients with CRSsNP also stand in partial contrast to our past studies of B cells in patients with CRS. In previous studies plasmablasts, B cell-activating cytokines (eg, BAFF), and immunoglobulins of every isotype except IgD and class-switched autoreactive antibodies have been increased in NP tissue of patients with CRSwNP. 12, 17, 29, 33 In contrast to CRSwNP, CRSsNP is both clinically and molecularly more heterogeneous. 33 Thus, given the association of IgD with CRSsNP, we further evaluated the relationships between a variety of locally expressed mediators, including CD40L, BAFF, IFN-g, IL-2, IL-4, IL-10, IL-15, and IL-21 and with tissue IgD levels because these factors had previously been shown to induce differentiation of IgD plasmablasts in vitro. 24 We observed that IL-2 levels were significantly increased in tissue of patients with CRSsNP in concordance with another study. 43 Furthermore, these levels were positively correlated with tissue IgD levels in vivo (r 5 0.41), and ex vivo IL-2-stimulated nasal tissue explants from patients with CRSsNP also produced significantly more sIgD than control tissue explants. The dependence on IL-2 for IgD secretion has previously been reported by Arpin et al 44 on tonsil-derived B cells in vitro, and this study further supports the concept that this mechanism might be relevant in vivo. Because IL-2 is only transiently secreted by T cells in the acute phases of an infection 45 and patients with CRS with positive bacterial culture results or recent antibiotic use had higher levels of IgD in this study, these findings could be interpreted as evidence that sIgD and IgD 1 plasmablasts can play an immune role in bacterial exacerbations of CRS. Future in vivo and in vitro studies will be required to investigate the relationship between IgD levels and bacterial infection.
In summary, increased levels of sIgD and abundant IgD 
METHODS Subjects
All patients with CRS met the clinical criteria for CRS, as defined by the American Academy of Otolaryngology-Head and Neck Surgery Chronic Rhinosinusitis Task Force and underwent routine functional endoscopic sinus surgery.
E1,E2 Patients with established immunodeficiency, pregnancy, coagulation disorder, classic allergic fungal sinusitis, isolated antrochoanal polyps, or cystic fibrosis were excluded from the study. The presence of sinusitis or NPs was confirmed by means of office endoscopy and computed tomographic imaging. Control subjects without a history of CRS undergoing nasal surgery for a variety of non-CRS indications (eg, septoplasty or approaches to the orbit or anterior skull base) were recruited from the otolaryngology clinic at Northwestern University.
Sample collection and preparation
Standardized nasal tissue samples consisting of UT and NPs were obtained during routine functional endoscopic sinus surgery. Specimens from control subjects were obtained during endoscopic skull base tumor excisions, intranasal procedures for obstructive sleep apnea, and facial fracture repairs for patients without a history of sinonasal inflammation. After removal, weighed tissue samples were placed in PBS-Tween supplemented with a cocktail of protease inhibitors (Sigma-Aldrich, St Louis, Mo) added at a 1:100 dilution. For total protein extraction, samples were homogenized with a Bullet Blender Blue (Next Advance, Averill Park, NY), according to the manufacturer's instructions. The samples were then centrifuged at 4000 rpm for 20 minutes at 48C, and the supernatants were frozen at 2208C until analysis.
Nasal lavage fluid was also obtained before initiating surgery from control subjects and patients with CRS. After suctioning the nasopharynx, 8 mL of PBS was sprayed through a syringe toward the middle meatus, and resultant fluid was collected with a Lukens trap (Covidien, Mansfield, Mass). Collected nasal lavage fluid was spun down for 10 minutes at 3000 rpm, with the resulting supernatant concentrated by means of centrifugation in a Amicon Ultra-4 10K Centrifugal Filter Unit (EMD Millipore, Temecula, Calif) at 3000 rpm for 10 minutes at 48C. The supernatant was stored at 2208C until use.
Blood samples were also collected before initiating surgery from control subjects and patients with CRS for IgD measurements in the serum.
Immunofluorescence
Paraffin-embedded tissue sections were rehydrated, treated with antigen retrieval unmasking reagent (Vector Laboratories, Burlingame, Calif), rinsed, and blocked with 5% goat serum (Vector Laboratories) for at least 1 hour. Then the sections were incubated with phycoerythrin-conjugated goat anti-human IgD antibody (1:400; SouthernBiotech) overnight at 48C. After washing, slides were mounted with SlowFade Gold Antifade Reagent with 4,6-diamidino-2-phenylindole counterstain (Life Technologies, Grand Island, NY) and stored in the dark at 48C. Representative images from immunofluorescence slides were obtained with an Olympus IX71 inverted research microscope (Olympus, Center Valley, Pa) by using a 3200 or 3400 objective lens and a MicroFire AR digital microscope camera (Optronics, Goleta, Calif).
The number of positive cells in 5 random fields was counted in 5 sections at a magnification 3400 from each tissue specimen. Each section was randomly selected, and diagnosis was blinded to the observers.
Cell isolation and flow cytometry
ET collected into cold RPMI 1640 medium (Life Technologies) supplemented with 3% FCS (Atlanta Biologicals) during sinus surgery were processed within 2 hours. To increase the number of isolated cells, we obtained ET instead of UT. Bone and cartilage was removed, and ET was minced into small pieces, followed by digestion with 0.25 mg/mL collagenase IV (Sigma-Aldrich) for 1 hour at 378C. The softened tissue was then placed between 2 frosted ends of microscope slides, gently ground, and filtered through a 70-mm Falcon cell strainer (Thermo Fisher Scientific). The filtrate was layered atop FCS and centrifuged at low speed (300g) to remove additional debris and yield a pellet of monodispersed cells. In addition, blood from the same subjects was collected into heparin-containing vacutainers and lysed with standard ACK RBC lysis buffer to obtain erythrocyte-free leukocytes.
For flow cytometric analysis, cell viability and absolute counts were assessed with ethidium bromide/acridine orange vital staining under a fluorescent microscope. Cells were resuspended in staining medium at approximately 10 8 cells/mL and first incubated with an Fc Block reagent (Miltenyi Biotec, Auburn, Calif) for 10 minutes at room temperature, followed by staining with the amine reactive dye Zombie Aqua (BioLegend, San Diego, Calif) to mark dead cells. All antibodies were obtained from BioLegend, except for IgM (BD Bioscience) and BLIMP-1 (Novus Biologicals, Littleton, Colo). The following fluorophore-conjugated mAbs and dilutions were used to stain the surface of cells: CD3 (clone UCHT1), CD14 (M5E2), CD16 (3G8), CD19 (HIB19), CD20 (2H7), CD27 (O323), CD38 (HIT2), CD45 (HI30), CD56 (HCD56), CD138 (MI15), IgD (IA-62), and IgM (G20-127). According to the procedures for surface marker staining, cells were fixed/permeabilized by using Cytofix/Cytoperm Kit (BD Biosciences), according to the manufacturer's instructions, and stained with fluorescent antibody reagents specific for intracellular IgD (clone IA-62) and BLIMP-1 (clone 3H2-E8).
By using FlowJo software (FlowJo), all samples were subjected to a sequential gating strategy to remove first dead cells (Zombie Aqua 
Real-time PCR
Total RNAs were isolated from whole-tissue extracts, and cDNA was prepared, as previously described.
E3,E4 Briefly, total RNAs were isolated from whole-cell extracts and treated with DNase I by using NucleoSpin RNA II (MACHEREY-NAGEL, Bethlehem, Pa), according to the manufacturer's instructions. The quality of total RNA was assessed by using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, Calif) with an RNA 6000 Nano LabChip (Agilent Technologies). Single-strand cDNA was synthesized from 0.5 mg of total RNAs with SuperScript II reverse transcriptase (Invitrogen, Carlsbad, Calif) and random primers. Semiquantitative real-time PCR was performed with a TaqMan method by using an Applied Biosystems 7500 Sequence Detection System (Applied Biosystems, Foster City, Calif) in 20 mL reactions ( 
Nasal swab culture
To obtain the specimens, the swab was left in the middle meatus or sinus cavity of patients for a few seconds until moistened and was rolled back and forth gently and then carefully removed. The samples were collected with 2 swabs per patient. For aerobic microbiological examination, quantitative cultures were processed according to the standard laboratory protocol, and Gram staining was performed. The swab specimens were inoculated directly onto the aerobic media, including sheep blood agar, chocolate agar, and a Macconkey agar. All plates were incubated at 358C for 24 hours. If there was no bacterial growth, medium was further incubated for 24 hours more before it was reported as negative. In addition, Gram staining was performed in smear, and the presence of any microorganisms and white blood cells was identified. ; Fig E1, A) and then gated based on forward scatter A (FSC-A) versus FSC-H for monodispersed cells or singlets (Fig E1, B) . C, Next, cells were gated out based on a dump channel indicating positive staining for T cells (CD3 
